Journal
BIOMARKER RESEARCH
Volume 9, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40364-021-00291-y
Keywords
-
Categories
Funding
- University of East Anglia from the UK Research and Innovation (UKRI) Biotechnology and Biological Sciences Research Council (BBSRC) under grants National Capability in Genomics and Single Cell [BBS/E/T/000PR9816]
- Earlham Institute from the UK Research and Innovation (UKRI) Biotechnology and Biological Sciences Research Council (BBSRC) under grants National Capability in Genomics and Single Cell [BBS/E/T/000PR9816]
- Wellcome Trust
- Rosetrees Trust
- University of East Anglia
- Big C
- Norwich and Norfolk University Hospital
- Abbvie
- Jannsen
Ask authors/readers for more resources
Despite recent advances in treatment, acute myeloid leukemia (AML) remains an incurable malignancy. However, the combination treatment of Venetoclax and Daratumumab may potentially slow tumor progression and reduce leukemia growth in both in vitro and in vivo settings, providing evidence for clinical evaluation.
Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
